Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bloomage BioTechnology's Total Assets for the quarter that ended in Mar. 2026 was ¥8,750 Mil.
Warning Sign:
If a company builds assets at 16.2% a year, faster than its revenue growth rate of 7.5% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Bloomage BioTechnology's average Total Assets Growth Rate was -2.20% per year.
During the past 3 years, the average Total Assets Growth Rate was 5.40% per year.
During the past 5 years, the average Total Assets Growth Rate was 16.20% per year.
During the past 10 years, the average Total Assets Growth Rate was 32.70% per year.
During the past 10 years, Bloomage BioTechnology's highest 3-Year average Total Assets Growth Rate was 58.50%. The lowest was 5.40%. And the median was 33.20%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Bloomage BioTechnology's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Bloomage BioTechnology Total Assets Related Terms
Bloomage BioTechnology Total Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Bloomage BioTechnology's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bloomage BioTechnology (SHSE:688363) has a Total Assets of ¥8,750 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Bloomage BioTechnology and its competitors.
Is Bloomage BioTechnology's Total Assets too high?
Bloomage BioTechnology's current Total Assets is ¥8,750 Mil. Overall, Bloomage BioTechnology has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bloomage BioTechnology's Total Assets compare to LIN and SHW?
Bloomage BioTechnology's Total Assets of ¥8,750 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Chemicals company?
A good Total Assets depends on the Chemicals industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Bloomage BioTechnology and its competitors. Bloomage BioTechnology's current Total Assets is ¥8,750 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bloomage BioTechnology stock overvalued right now?
Based on GuruFocus' analysis, Bloomage BioTechnology (SHSE:688363) is currently considered Fairly Valued. The stock's GF Value™ is ¥42.77, compared to a current price of ¥39.19 — trading 8.4% below its estimated fair value. The current Total Assets is ¥8,750 Mil. Bloomage BioTechnology's overall GF Score™ is 94/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Bloomage BioTechnology (SHSE:688363), the current Total Assets is ¥8,750 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bloomage BioTechnology (SHSE:688363) Overvalued in 2026?
Based on GuruFocus' analysis, Bloomage BioTechnology stock appears to be undervalued.
The current stock price of ¥39.19 is trading 8.4% below its estimated GF Value™ of ¥42.77.
GuruFocus considers Bloomage BioTechnology to be Fairly Valued.
Key valuation signals for SHSE:688363:
Total Assets: ¥8,750 Mil
GF Value™: ¥42.77 vs. price of ¥39.19 (8.4% below fair value)
No single metric tells the full story. See the SHSE:688363 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bloomage BioTechnology Corp Ltd manufactures and sells a variety of chemicals and chemical-based products, typically made from hyaluronic acid or sodium hyaluronic acid. The company's products include raw materials, medical products, functional skincare, and functional foods. Raw materials, mainly hyaluronic acid, are used in pharmaceuticals, medical devices, cosmetics, and food. Medical products span beauty and therapeutic uses, such as viscoelastics, lubricants, fillers, and skin protectors. Skincare items include lotions, creams, and masks, while functional foods feature hyaluronic acid drinks and supplements.
94GF Score
Get the complete analysis for SHSE:688363
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688363 has been successfully added to your 
